SCHEMBL20697247

SCHEMBL20697247

CCOC(=O)c1cnn2c(N(Cc3ccccc3)Cc3ccccc3)cc(Nc3ccnn(-c4ccc(F)cc4)c3=O)nc12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 7/20 0.54
▸ ALDH1A1 P00352 8/20 0.43
▸ HPGD P15428 5/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ HSD17B10 Q99714 4/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ TSHR P16473 2/20 0.41
▸ CASP1 P29466 2/20 0.40
▸ CASP7 P55210 2/20 0.40
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.37
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20687954 0.91 TYK2 (0.61) TYK2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL20687953 0.89 TYK2 (0.70) TYK2
SCHEMBL20696802 0.81 TYK2 (0.61) TYK2
SCHEMBL21948513 0.80 TYK2 (0.60) TYK2
SCHEMBL20688848 0.80 TYK2 (0.54) TYK2ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL21258424 0.74 TYK2 (0.58) TYK2ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL20678782 0.74 KDM4E (0.54) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL20689401 0.73 TYK2 (0.54) TYK2ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL21227342 0.73 KDM4E (0.48) TYK2ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL20678916 0.71 TYK2 (1.00) TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 — — US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 — — US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 — — US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 — — US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885HPGD 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback